RCS - BB Biotech AG - Edison issues review on BB Biotech (BION)
07/03/2023 10:00
For best results when printing this announcement, please click on link below: http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230307:nRSG1401Sa&default-theme=true RNS Number : 1401S BB Biotech AG 07 March 2023 London, UK, 7 March 2023 Edison issues review on BB Biotech (BION) According to BB Biotech's (BION's) investment team, the biotech industry remains in a very good position. Following a sell-off in the last two years, valuations are still close to the levels seen three years ago, reflecting ongoing challenges and despite the fundamental industry strength. In the sector, BION is differentiated from the Nasdaq Biotechnology Index by its concentrated portfolio (c 30 stocks). The investment team anticipates that 2023 will include multiple catalysts for the sector and for BION portfolio companies, including product launches, important clinical trial results, licensing deals and renewed M&A activity. During 2022 the investment manager, Bellevue Asset Management, strengthened the investment team with three new members (two data scientists and one neurologist). BION's current 19.7% premium to NAV is close to its historical average of c 19% over one year and above 14% over five years. On 20 January 2023 the company announced that the board will propose a regular dividend of CHF2.85 per share at the annual general meeting on 23 March, corresponding to 5% of the average volume weighted share price of December 2022, consistent with the dividend policy introduced in 2013. Click here (https://www.edisongroup.com/research/picking-growth-at-good-value/32043/?utm_campaign=RNSreach%20Press%20Releases&utm_source=RNSreach&utm_medium=Press%20Release) to view the full report or here (https://share.hsforms.com/14ENcGBFTQfmT6UkoLH7ZgA3k1vq) to sign up to receive research as it is published. All reports published by Edison are available to download free of charge from its website www.edisongroup.com (http://www.edisongroup.com) About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors. By focusing on the volume and quality of investors reached - across institutions, family offices, wealth managers and retail investors - Edison can create and gauge intent to purchase, even in the darkest pools of capital, and then make introductions via non-deal roadshows, events or virtual meetings. Having been the first in-market 17 years ago, Edison now has more than 100 analysts covering every economic sector. Headquartered in London, Edison also has offices in New York, Frankfurt, Amsterdam and Tel Aviv and a presence in Athens, Johannesburg and Sydney. Edison is authorised and regulated by the Financial Conduct Authority (https://register.fca.org.uk/ShPo_FirmDetailsPage?id=001b000000MfYL6AAN) . Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities. For more information, please contact Edison: Victoria Chernykh +44 (0)20 3077 5700 investmenttrusts@edisongroup.com (mailto:investmenttrusts@edisongroup.com) Learn more at www.edisongroup.com (http://www.edisongroup.com) and connect with Edison on: LinkedIn www.linkedin.com/company/edison-group-/ (http://www.linkedin.com/company/edison-group-/) Twitter www.twitter.com/Edison_Inv_Res (http://www.twitter.com/Edison_Inv_Res) YouTube www.youtube.com/edisonitv (http://www.youtube.com/edisonitv) This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com (mailto:rns@lseg.com) or visit www.rns.com (http://www.rns.com/) . Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy) . END NRAFIFETVLIDIIV